NRX Pharmaceuticals Inc. Advances in Clinical Research

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company based in Wilmington, United States, continues to make strides in the development of investigational medicines. Specializing in treatments for Covid-19, respiratory conditions, suicidal depression, and PTSD, the company remains committed to addressing critical health challenges.

As of August 21, 2025, NRX Pharmaceuticals’ stock closed at $2.64 on the Nasdaq, reflecting a significant recovery from its 52-week low of $1.10 on October 15, 2024. Despite this recovery, the stock has yet to reach its 52-week high of $6.01, recorded on January 12, 2025. The company’s market capitalization stands at $46,160,000 USD, with a price-to-earnings ratio of -1.233, indicating ongoing investments in research and development.

Founded in 2017, NRX Pharmaceuticals has focused its efforts on innovative therapies, particularly in the realm of respiratory diseases and mental health. The company’s research into Covid-19 treatments and vaccines remains a priority, alongside its work on addressing suicidal depression and PTSD.

For more information on NRX Pharmaceuticals’ ongoing projects and developments, interested parties can visit their website at www.nrxpharma.com or follow their trading activities on the Nasdaq stock exchange.